BioCryst’s Oral Therapy For HAE Attacks On Track With Exploratory Phase II Success

Biocryst’s oral kallikrein inhibitor BCX7353 – already in Phase III for prophylaxis of hereditary angioedema – shows efficacy in a range of endpoints in a Phase II exploratory trial.